Aevice Health announced that its flagship medical system, a wearable stethoscope for respiratory well being monitoring, has been approved by Singapore’s Health Sciences Division.
AeviceMD, an AI-powered wearable chest-mounted stethoscope, detects and records irregular breath sounds like wheezing and displays vital indicators like coronary heart rate and respiration rate.
According to press reports, the monitoring system system is appropriate for children aged 3 and up and is approved for both medical and residential use.
Why it matters
Singapore has one of the world’s highest rates of bronchial asthma and COPD. Bronchial asthma affects about 5% of adults and 20% of children in the United States, whereas COPD is one of the top ten causes of death.
Aevice Health aims to use remote health monitoring expertise to reduce ED signs and readmissions in patients suffering from these chronic respiratory illnesses. AeviceMD aids in the early detection of potential deterioration by providing medical professionals with a summary of a patient’s lung health.
According to the company, it intends to use HSA approval as a starting point for expanding the reach of its expertise to populations with severe respiratory illness.
The overall trend
Market approval will come two years after Aevice Health first conducts the study. AeviceMD’s clinical trial with the National University Health System is looking into its use in pediatric patients with respiratory issues.
In addition to Singapore, this system will be launched in Japan in 2021 with $2 million from a pre-series A funding round.
